

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/064056 A2

(51) International Patent Classification:
A61M 1/36 (2006.01)

(21) International Application Number:
PCT/EP2005/056879

(22) International Filing Date:
16 December 2005 (16.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
04029796.2 16 December 2004 (16.12.2004) EP
60/636,527 17 December 2004 (17.12.2004) US

(71) Applicant (for all designated States except US): NOLABS
AB [SE/SE]; Kungsgatan 6, S-252 21 Helsingborg (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): PETERS, Tor
[SE/CH]; Chalet Marabou Bodemos, CH-1659 Rougemont (CH).

(74) Agent: KRAHBICHLER, Erik; Ström & Gulliksson AB,
Järnvägsgatan 3, S-252 24 Helsingborg (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-PATHOGEN AND ANTI-CANCER FILTERING DEVICE AND METHODS COMPRISING THE USE OF NITRIC OXIDE



(57) Abstract: A filtering device and method are disclosed being adapted to eliminate, inactivate and/or remove pathogenic or cancerous elements, especially microorganisms, such as bacteria, parasites, fungi, mycoplasma, protozoa and viruses, or tumour cells from body fluids or fluids getting into contact with the body, by using NO originating from the filtering device material. Exemplary embodiments comprise blood filters, or breathing gas filters. Also, uses of nitric oxide are disclosed for the treatment of various diseases, e.g. blood borne cancers, such as leukaemia.

**ANTI-PATHOGEN AND ANTI-CANCER FILTERING DEVICE AND METHODS
COMPRISING THE USE OF NITRIC OXIDE****Field of the Invention**

5 This invention pertains in general to the field of
medical fluid treatment. More particularly the invention
relates to filters for medical devices used to effectively
eliminate, inactivate and/or remove pathogenic and/or
cancerous elements, for instance microorganisms, such as
10 bacteria, parasites, fungi, mycoplasma, protozoa, and
viruses, or especially cancer / tumour cells, from fluids,
especially body fluids or fluids getting into contact with
the body.

15 Background of the Invention

In a variety of circumstances, pathogenic elements,
especially microorganisms, such as bacteria, parasites, as
e.g. malaria, protozoa and viruses, and/or cancerous
elements, such as tumour cells, e.g. leukaemia, must be
20 eliminated, inactivated and/or removed from body fluids
such as blood or respiratory gases. This is generally done
for the purpose of treatment of a disease related to said
pathogenic and/or cancerous elements. Often, when a disease
related to the elements is already present in a patient,
25 the elimination, inactivation and/or removal is done in
order to reduce the number of the elements in the body, so
that a medical treatment is facing less antagonists, and
becomes thus more effective. Alternatively, the elements in
question are hindered from entering or leaving a body in
30 order to reduce the risk for transferring contagious or
infectious elements to or from a body.

Membrane filtration is one known way of removing such
pathogenic elements, wherein particles are separated by
size exclusion based on a sieving principle. Therefore,
35 filtration is limited to the removal of such pathogenic

elements by size irrespective of chemical or thermal characteristics thereof.

Furthermore, various methods of inactivating pathogenic or cancerous elements in fluids are known, e.g. heat treatment, radiation treatment or chemical treatment methods. However, the heat treatment method exerts little effect on certain heat-resistant pathogenic elements, e.g. human parvovirus B19, hepatitis A virus, and the like. Moreover, known chemical treatment methods have essentially no effect on certain types of pathogenic elements, e.g. human parvovirus B19, poliovirus, reovirus, and SV-40 having no lipid envelope. In particular, the virus removal membrane is, as of today, in certain cases the only effective device for inactivating or removing pathogens. This is for instance the case for the human parvovirus B19, which is both heat resistant and has no lipid envelope. Chemical, and especially radiation treatment has often unwanted vigorous side effects.

Removal membranes for pathogenic elements available at present are either based on a membrane, which allows high-molecular-weight physiologically active products such as human immunoglobulin and Factor VIII to pass there through, but exhibits inferior small virus removal performance, or a membrane which can remove small viruses, but cannot allow high-molecular-weight physiologically active products such as human immunoglobulin or Factor VIII to pass there through at a practical level.

WO 2004/012874 discloses a nitric oxide releasing medical device intended to be used during surgery. The device comprises a substrate to which an amine-functionalized silane residue can be bound, such as a metallic surface, and nitric oxide bound to the substrate through NO-releasing nucleophiles, which are bonded to said amine-functionalized silane residue. Examples of the amine-functionalized silane residue is trimethoxysilyl-modified

polyethyleneimine and methyldimethoxysilyl-modified polyethyleneimine. However, the device according to WO 2004/012874 has the disadvantage of uncontrollable release of NO since the release is dependent on a silane residue, and nothing is mentioned about treating blood borne tumours. Furthermore, the device according to WO 2004/012874 fails to present a fibrous structure, which structure is advantageous in respect of obtaining efficient filtering and effective treatment.

US 2004/0131753 discloses a coating for medical devices, which coating provides NO delivery by using nanofibers of L-PEI. However nothing in US 2004/0131753 is mentioned about how NO is released from the coating in D2, and in particular nothing is mentioned about the ability to release NO in contact with blood. Also, nothing is mentioned in US 2004/0131753 about a good filtering characteristic as a result of a fibrous structure. Furthermore, nothing is taught about treating cancer, such as blood borne tumours, such as leukaemia. US 6,656,217 describes a device adapted for exposure to blood flowing in a living being and having a surface which is exposed to the blood and which is coated with a physiologically acceptable polymer which contains a nitrosyl-containing organometallic compound. Thus, it is not the physiologically acceptable polymeric material of the tubing, etc., that elutes nitric oxide in US 6,656,217, but the nitrosyl-containing organometallic compound contained in the physiologically acceptable polymer. Furthermore, nothing is mentioned in US 6,656,217 about treating blood borne tumours, such as leukaemia.

US 2004/093015 discloses an embolism protection device that may elute biologically active agents. On page 5, paragraph 70, US 2004/093015 mentions nitric oxide as a vasodilating agent. Nothing is mentioned in US 2004/093015 about treating blood borne tumours, such as leukaemia, and

nothing is mentioned about the advantage of a fibrous material in respect of a filtering device.

Hence, there are no adequate therapies available for a number of diseases where for instance blood carried
5 pathogenic elements, such as viruses, or cancerous elements play a central role. Moreover, an increasing number of viruses and the currently ongoing mutations of e.g. bird flu viruses create a need for innovative ways of effective treatment. Hence, an alternative and/or improved way of at
10 least partly eliminating, inactivating and/or removing pathogenic elements or cancerous elements from body fluids or fluids getting into contact with the body would be advantageous.

15 **Summary of the Invention**

Accordingly, the present invention preferably seeks to mitigate, alleviate or eliminate one or more of the above-identified deficiencies in the art and disadvantages singly or in any combination and solves, among others, for
20 instance the above mentioned problems by providing a filtering device, a manufacturing process therefor, a method, and medical uses, according to the appended patent claims.

According to one aspect of the invention a filtering
25 device adapted to eliminate, inactivate and/or remove pathogenic and/or cancerous elements from fluids, especially body fluids or fluids getting into contact with the body is provided. The device comprises a nitric oxide (NO) eluting polymer arranged to contact said fluid when in
30 use of said filtering device passing there through, such that a therapeutic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said fluid, said nitric oxide (NO) eluting polymer is a fibrous nitric oxide (NO) eluting polymer, and said nitric oxide is controllably

elutable from said fibrous nitric oxide (NO) eluting polymer upon contact with said body fluid.

The filtering device may comprise microorganisms comprised in the group of bacteria, parasites, fungi, mycoplasma, protozoa, and viruses, and wherein said cancerous elements may be tumour cells.

The fluid may be a blood, wherein said filtering device may be comprised in an extracorporeal circuit configured to transport blood from a patient and/or after treatment of blood returns treated blood to the patient.

The extracorporeal circuit may be comprised in an extracorporeal blood treatment apparatus, particularly comprised in the group comprising a dialysis apparatus, an oxygenator, or arbitrary combinations thereof.

The filtering device may be an embolism filter.

The filtering device may be configured to treat a blood-borne tumour, wherein the blood borne tumour may be leukaemia.

The body fluid may be inspiratory or expiratory gas entering or leaving a mammal body through the mouth or nose thereof.

The fibrous nitric oxide (NO) eluting polymer may be configured to trigger release NO from the fibrous nitric oxide (NO) eluting polymer by contact with humidity from said body fluid.

The fibrous polymer may be linear poly(ethylenimine) (L-PEI).

The fibrous nitric oxide (NO) eluting polymer may comprise nanofibers arranged as or on a filter medium of the filtering device. The nanofibers may comprise poly(ethylenimine)-diazoniumdiolate.

According to a further aspect of the invention, a process for forming a filtering device adapted to eliminate, inactivate and/or remove pathogenic elements, especially microorganisms, such as bacteria, parasites,

protozoa and viruses, or cancerous elements from fluids is provided. The process comprises selecting a plurality of nitric oxide eluting polymeric fibers, and deploying said nitric oxide eluting fibers to be comprised in a filter
5 membrane.

The deploying of fibres may comprise electrospinning of nanofibers of poly(ethylenimine)-diazeniumdiolate, comprising depositing of the nanofibers on the filtering device.

10 According to a further aspect of the invention, a method for eliminating, inactivating and/or removing pathogenic elements, especially microorganisms, such as bacteria, parasites, fungi, mycoplasma, protozoa and viruses, or cancerous elements from fluids, is provided.

15 The method comprises providing a filtering device comprising a fibrous nitric oxide eluting polymer, and eluting nitric oxide from the polymer upon contact with the fluid for achieving an anti-pathogenic and/or anti-cancerous effect.

20 According to another aspect of the invention, a use of nitric oxide (NO) for adding anti-pathogenic and/or anti-cancerous functionality to an extra corporeal medical filtering device is provided.

25 According to a further aspect of the invention, a use of nitric oxide (NO) eluting polymers for elution of NO from a medical filtering device for adding anti-pathogenic and/or anti-cancerous functionality to the medical filtering device is provided.

30 According to a yet further aspect of the invention, a use of a nitric oxide eluting filtering device for the treatment of blood borne tumour is provided. The blood borne tumour may be leukaemia.

35 According to a further aspect of the invention, a use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the

treatment of a blood-borne tumour is provided, wherein the blood borne tumour may be leukaemia.

According to a further aspect of the invention, NO for the treatment of a blood borne tumour is provided. The
5 blood borne tumour may be leukaemia.

According to a further aspect of the invention, NO for the treatment of bird flu is provided.

According to a further aspect of the invention, a use of an NO eluting polymer for the manufacture of a
10 medicament incorporated in a filtering device for the treatment of bird flu is provided.

According to a further aspect of the invention, NO for the treatment of Transmissible Spongiform Encephalopathies is provided.

15 According to a further aspect of the invention, a use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the treatment of Transmissible Spongiform Encephalopathies is provided.

20 According to a further aspect of the invention, NO for the treatment of Creutzfeldt-Jacob Disease is provided.

The present invention has for instance according to some embodiments at least the advantage over the prior art that it provides effective exposure of a body fluid or
25 particles therein, e.g. blood particles or any other particles contained in blood, to be homogeneously exposed to NO eluted from a fibrous polymer, whereby a very effective anti-viral, anti-bacterial, anti-fungi and/or anti-cancer therapy is achievable.

30

Brief Description of the Drawings

These and other aspects, features and advantages of which the invention is capable of will be apparent and elucidated from the following description of embodiments of

the present invention, reference being made to the accompanying drawings, in which

Fig. 1 is a schematic illustration of embodiments of the invention with reference to a patient;

5 Fig. 2 is a schematic illustration of a fibre filtering layer comprised in an embodiment of the invention;

Fig. 3 is a schematic illustration of a multi-layer blood filter according to an embodiment of the invention;

10 Fig. 4 is a schematic illustration of a breathing gas filter according to another embodiment of the invention; and

Fig. 5 is a schematic illustration of another breathing gas filter according to another embodiment of the invention.
15

Description of embodiments

The following description focuses on different embodiments of the present invention applicable to an apparatus treating human blood whilst outside the body, respiratory filters, e.g. a breathing mask, and other types of filtering devices. However, it will be appreciated that the invention is not limited to these applications mentioned in the different embodiments, but may be applied
20 to many other similar areas where fluids are filtered, including for example water purification systems, purification systems used within the pharmaceutical industry, air filtration systems, etc.

However, all embodiments have in common that Nitric
30 Oxide is used, taking advantage of its anti-pathogenic and anti-cancerous effect.

Nitric Oxide

Hitherto Nitric Oxide (NO) has been used for
35 improving healing processes of implanted medical devices.

This improvement of healing is partly caused by NO inhibiting the activation or aggregation of blood platelets, and also by NO causing a reduction of inflammatory processes at the site of an implant.

5 NO is also known to have an anti-pathogenic, especially an anti-viral, effect, and furthermore NO has an anti-cancerous effect, as it is cytotoxic and cytostatic in therapeutic concentrations, i.e. it has among other effects tumoricidal and bacteriocidal effects. NO has for instance
10 cytotoxic effects on human haematological malignant cells from patients with leukaemia or lymphoma, whereby NO may be used as a chemotherapeutic agent for treating such haematological disorders, even when the cells have become resistant to conventional anti-cancer drugs. This anti-
15 pathogenic and anti-tumour effect of NO is taken advantage of by the present invention, without having adverse effects as for instance many anti-cancer drugs. Also the present invention provides a solution to how nitric oxide may be released to body fluids in a therapeutical way.

20 However, due to the short half-life of NO, it has hitherto been very hard to treat viral infections with NO and it is difficult if not impossible until now to expose larger amounts of body fluids to NO. This is because NO is actually toxic and has negative effects when applied in too
25 large amounts to the body. NO is actually also a vasodilator, and too large amounts of NO introduced into the body will cause a complete collapse of the circulatory system. On the other hand, NO has a very short half-life of fractions of a second up to a few seconds, once it is
30 released. Hence, administration limitations due to short half-life and toxicity of NO have been limiting factors in the use of NO in the field of anti-pathogenic and anti-cancerous treatment so far.

The applicants of the present invention's new
35 technology build on the concept of reducing the amount of

fluid, e.g. blood or respiratory gas, carried pathogenic elements, e.g. viruses, bacteria, fungi, mycoplasma, cancerous elements etc. This is established by exposing the fluid, e.g. blood comprising blood cells, to NO by means of
5 an extracorporeal "filter" device. The "filter" device is fully or partly consisting of polymer filaments eluting NO when in contact with the body fluid. In this way, an anti-bacterial, anti-viral, anti-fungi, anti-cancer, etc. element is provided for reducing pathogenic and/or
10 cancerous elements, especially microorganisms, such as bacteria, parasites, fungi, protozoa, and viruses, or cancer / tumour cells, from fluids. The fibrous structure of the device according to the present invention provides a major advantage in respect of filtering effect.

15 The expression "filter" in this context is directed towards a porous article or mass, as of cloth, paper, polymeric material, metal, etc., that serves as a medium for establishing a contact with a liquid or gas passed through it, so that matter held in suspension or dissolved
20 in the liquid or the gas may be separated thereof. However, the main purpose of the "filter" for the present invention is to expose the liquid or gas to nitric oxide supplied by means of the "filter", rather than filtering out the pathogenic elements or matter. This means that the
25 pathogenic and/or cancerous elements are at least to be immobilised or rendered innocuous by the "filter", and the possibility of binding these immobilised, i.e. no longer pathogenic or carcinogenic, elements to the filter is only a secondary possibility offered by the nature of the
30 filtering device, which is advantageous for certain applications.

The filter device comprises a high number of filaments, which allows a high number of blood molecules to be exposed to NO on an individual basis. An exemplary, non-
35 limiting filament arrangement is shown in Fig. 2. The

filter device may have the NO eluting polymer coated onto its filter membrane or it may comprise the polymer as a structural material through which the fluid to be treated passes in use of the filter. The polymer may be any
5 suitable material capable of storing NO in a sufficient amount. The filtering device comprising the polymer shall be storable over a longer time without a substantial loss of stored NO, so that it is fully functional at the time of use. A preferred material is L-PEI, explained in more
10 detail below. Other example for NO eluting polymers are given in US-5,770,645, wherein polymers derivatized with at least one -NOX group per 1200 atomic mass unit of the polymer are disclosed, X being one or two. One example is an S-nitrosylated polymer and is prepared by reacting a
15 polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups. Other examples disclosed are S-nitrosylated .beta.-cyclodextrin or an S-nitrosylated .beta.-cyclodextrin complexed with S-nitroso-N-acetyl-D,L-penicillamine or S-
20 nitroso-penicillamine, S-nitrosylated .beta.-cyclodextrin and S-nitrosylated .beta.-cyclodextrin complexed with S-nitroso-N-acetyl-D,L-penicillamine. Compositions comprising S-nitrosylated cyclodextrins complexed with S-nitrosothiols, have been found to deliver NO-related
25 activity for extended periods of time and to exhibit good shelf stability.

According to one embodiment, the filter device is comprised in an improved oxygenator assembly, currently used in open heart surgery. According to another
30 embodiment, the filter device is comprised in an artificial kidney assembly, as currently used in dialysis.

Adding NO eluting technology, preferably nano-fiber technology of L-PEI, converts existing filtering devices into therapeutic devices.

One of the advantages of the NO-eluting nano-fiber technology is a constant and non-toxic elution of NO into the body fluid and exposure of all naturally occurring cells, virus and other particles e.g. bacteria to NO.

5 Toxicity is avoided by a combination of local NO elution and the short half-life of NO.

Exposure and contact between particles suspended in body fluids and NO is guaranteed by the presence of a large number, e.g. some millions, of NO-eluting nano-fibers.

10 This technology, for instance applied in a blood filtering device, significantly reduces the amount of active blood carried virus such as Hepatitis, HIV, Ebola and Influenza allowing drug therapy to become more effective treating residuals.

15

Linear poly(ethylenimine) L-PEI

Akron University has developed NO-eluting L-PEI molecule that can be nano-spun onto the surface of medical devices such as implanted grafts, showing significant
20 improvement of the healing process and reduced inflammation when implanting such devices. This is for instance described in US-6,737,447. According to US-6,737,447, a coating for medical devices provides nitric oxide delivery using nanofibers of linear poly(ethylenimine)-
25 diazeniumdiolate. Linear poly(ethylenimine)diazoniumdiolate releases nitric oxide (NO) in a controlled manner to tissues and organs to aid the healing process and to prevent injury to tissues at risk of injury. Electrospun nano-fibers of linear poly(ethylenimine) diazeniumdiolate
30 deliver therapeutic levels of NO to the tissues surrounding a medical device while minimizing the alteration of the properties of the device. A nanofiber coating, because of the small size and large surface area per unit mass of the nanofibers, provides a much larger surface area per unit

mass while minimizing changes in other properties of the device.

However, the disclosure is both silent concerning a filtering application of body fluids, and the anti
5 pathogenic potential of nitric oxide.

According to embodiments of the invention described below, such nanofibers, preferably electrospun onto filter devices or electrospun into filter devices, are used for achieving an anti-pathogenic and/or cancerous effect when
10 "filtering" body fluids or fluids getting into contact with the body.

For this purpose, L-PEI fibres are preferably produced by the technique of electrostatic spinning, also known within the fiber forming industry as electrospinning,
15 of liquids and/or solutions capable of forming fibers. Electrospinning is well known and has been described in a number of patents as well as in the general literature. The process of electrostatic spinning generally involves the introduction of a liquid into an electric field, so that
20 the liquid is caused to produce fibers. These fibers are generally drawn to a cathode for collection. During the drawing of the liquid, the fibers harden and/or dry. This may be caused by cooling of the liquid, i.e., where the liquid is normally a solid at room temperature; by
25 evaporation of a solvent, e.g., by dehydration (physically induced hardening); or by a curing mechanism (chemically induced hardening).

One of the major advantages of using electrostatically spun fibers is that these fibers may be
30 produced having very thin diameters, usually on the order of about 100 nanometers to about 25 microns, and more preferably, on the order of about 100 nanometers to about 1 micron. Thus, these fibers may be collected and formed into coatings for filters or non-woven membranes of filter
35 devices of any desired shape and thickness. It will be

appreciated that, because of the very small diameter of the fibers, the resultant coating or membrane has a very small interstices and high surface area per unit mass, which is an advantage for filtering applications.

5 US-6,737,447 discloses a method for the production of fibers of linear poly(ethylenimine) diazeniumdiolate using electrospinning techniques. Such fibers have very small diameters of less than 1 micron, and, more preferably, less than 400 nanometers. The fibers also have very high surface
10 areas per unit mass and are capable of releasing therapeutic levels of NO as needed. These fibres are highly effective in delivering NO in combination with implanted devices, towards tissues surrounding medical devices while minimizing the alteration of the properties of the devices.
15 The same applies to the embodiments of the present invention, wherein these fibres are effectively delivering NO to surrounding fluids flowing through a filter comprising the fibres.

This effectiveness of NO delivery is for instance
20 accomplished by using electrostatically spun nanofibers of polymeric NONOate to coat the filter membrane of the filtering device. A nanofiber coating, because of the small size and large surface area per unit mass of the nanofibers, provides a much larger surface area while
25 minimizing changes in other properties of the filter device. Nanofibers of poly(ethylenimine)diazeniumdiolate are preferably used for medical filtering devices according to the embodiments describe below. Alternatively,
nanofibres 20 are spun into filter elements 2, such as
30 filtering pads or sheets. Multiple such sheets may be arranged in a suitable way, e.g. piled up (as shown in Fig. 3) or folded to multiple layers, so that an effective contact of the fluid flowing through the filter device is achieved. Alternatively a plurality of filters may be used
35 subsequently.

The aforementioned poly(ethylenimine)-
diazoniumdiolate fibers release NO with a half-life in the
range of 6-30 hours at pH 7.4 and 37[deg.] C. Once
released, NO will contribute with its anti-pathogenic,
5 anti-viral, anti-bacterial, anti-fungi and/or anti-
cancerous effect.

The release of NO from this polymer is humidity
controlled. Thus, activation is triggered by e.g. body
fluids, such as blood, sweat or, if available in an
10 sufficient amount, air humidity. Hence, filtering devices
may be activated to release NO when taken out of a suitable
humidity less storage environment, such as plastic package
having a defined low or no humidity atmosphere inside, and
when getting into contact with sufficient activation
15 humidity. This occurs e.g. when getting into contact with a
body liquid on which the NO is to be employed, wherein this
is for instance blood or respiratory gases to be treated;
expiratory gas has e.g. 100% relative humidity at body
temperature.

20 As shown in Fig. 1, a patient 10 may benefit from
such filter devices 11, 12 comprising NO eluting polymers
in several ways. One possibility is to filter breathing
gases, both entering or leaving the body, by means of
filter device 11. Another possibility is to take a body
25 fluid, such as blood, feed it to filter device 12, and
return it to the body after treatment with NO in device 12.
Below, a number of embodiments are given in order to
illustrate these principles.

In one embodiment of the present invention the NO
30 eluting polymer is selected from polymers containing
diazoniumdiolate groups, S-nitrosylated polymer and O-
nitrosylated polymer, or any combination of these, which
groups may elute NO. These may for example be selected from
the group comprising poly(alkyleneimine)diazoniumdiolate,
35 L-PEI-NO (linear poly(ethyleneimine)diazoniumdiolate).

Said polymers are loaded with nitric oxide (NO) through the diazeniumdiolate group and arranged for release of the nitric oxide (NO) to eliminate, inactivate and/or remove pathogenic and/or cancerous elements, especially microorganisms, such as bacteria, parasites, fungi, mycoplasma, protozoa and viruses, or tumour cells from fluids, especially body fluids or fluids getting into contact with the body.

10 **Extracorporeal blood filtering**

An embodiment of the invention pertaining to extracorporeal blood filtering is described below with reference to Figs. 1, 2 and 3.

Numerous techniques have been developed for circulating blood of a patient outside the body in an "extracorporeal" circuit and then returning it to the patient, for instance during a surgical procedure or during a dialysis. For example, in dialysis for patients with kidney failure, blood is circulated extracorporeally and contacted with a large membrane surface separating the blood from a dialysis solution, and urea and other blood chemicals are migrated across the membrane to cleanse the blood, which is then returned to the patient. In ex vivo organ perfusion, such as liver perfusion for patients with liver failure, blood is circulated extracorporeally and perfused through a donor organ, typically a pig liver in the case of liver perfusion, before returning it to the patient. In cases of thermal treatment, blood is circulated out of the body and through a heat exchanger and returned to the body. In heart surgery, either or both ventricles of the heart may be isolated and surgically repaired while making use of the patient's lungs during the surgery. In left monovalentricular surgery, the left ventricle is isolated for surgery by cannulating the left atrium into an extracorporeal circuit, which pumps the blood into a

cannulated femoral artery or other arterial source to the arterial bed. In biventricular surgery, the right ventricle is isolated for surgery by cannulating the right atrium and feeding the blood extracorporeally to the pulmonary artery, and the left ventricle is isolated by cannulating the left atrium and feeding the oxygenated blood extracorporeally to a femoral or other artery for perfusion of the arterial bed.

Another example of extracorporeal circulation is cardiopulmonary bypass ("CPB"), the procedure of mechanically bypassing both the heart and lungs to allow the whole heart to be isolated for surgical repair. A CPB machine, consisting of a number of independent and discrete components linked together by plastic tubing, assumes the function of the heart and lungs by oxygenating the blood of the patient, returning the oxygenated blood to the body, and pumping it through patient's circulatory system. More particularly, in CPB the patient's inferior and superior venae cava are cannulated and the blood is ducted from the patient to a venous reservoir in the CPB circuit. From the venous reservoir, this circuit then connects to a pump, which circulates the blood. The blood is then oxygenated by being pumped through a gas exchange reservoir, i.e. the above-mentioned oxygenator, where oxygen is added and carbon dioxide is removed from the system. The next CPB element is the heat exchanger where the temperature of the blood can be altered and controlled. This device is typically coupled in parallel to the oxygenator. The last element of the extracorporeal circuit is typically a filter used to eliminate particulate matter accumulated in the extracorporeal system. The oxygenated blood then re-enters the body of the patient through another cannula in the arterial system. Other elements which are part of the CPB system but operated in parallel to the circuit include systems used to retain suctioned blood in the operative

field to return to the patient ("cardioplegia") and systems to filter and concentrate the cells also to be given to the patient through the CPB circuit (cell savers or hemoconcentrators).

5 The filtering device 3 according to an embodiment of the invention is used for eluting NO into blood of a patient 10, during one of the above-mentioned or similar treatments in which blood is conducted out of the patient body. Alternatively, the filtering device 3 may be used in
10 a "stand-alone" circuit, solely for taking advantage of the anti-pathogenic and/or cancerous effect, without additional therapy, such as oxygenation or dialysis.

 Therefore, in one embodiment the device according to the present invention is directed to extracorporeal blood
15 filtering of blood borne tumours, such as leukaemia. It was surprisingly found that the fibrous device according to the present invention had such a large effective surface area to obtain this effect.

 According to a more detailed embodiment, the filter
20 device is incorporated in an extracorporeal blood circulation apparatus. The apparatus comprises an inlet line 13 adapted to receive blood from a patient, an outlet line 14 adapted to return blood to the patient, a fluid circuit for fluid communication between the inlet and the
25 outlet line, at least one pump acting on the fluid circuit to circulate blood there through and out the outlet line, and one or more nitric oxide eluting filters 3, 12 between the inlet and the outlet. Such a blood fluid circuit includes for instance the monoventricular and biventricular
30 bypass circuits described above. The fluid circuit may also comprise a blood treatment portion such as a dialysis component, an organ perfusion component, a heat exchange component or an oxygenation component for blood treatment as discussed above.

Because of the very short half-life of nitric oxide in blood, a nitric oxide concentration in the circulating extracorporeal blood is achieved at a dosage effective to produce the desired anti-pathogenic or anti-cancerous effect in the extracorporeal circuit without harming the patient, due to the above mentioned vasodilatory effect of NO. Preferably the blood velocity in the extracorporeal circuit is adjusted in such a way that the NO concentration in the blood has a sufficiently low level to not cause harm to the patient after the blood is returned to the patient.

The level of NO administered to the blood is controlled by the amount of NO being able to elute from the NO eluting polymer of the filter device, preferably L-PEI, and by the rate of blood flow passing the filter device. With a known volume of the filter device, the NO concentration at the filter device may be calculated. For instance, a differential pressure sensor may be used to calculate the blood flow rate over the filter device according to known techniques. In combination with the polymer characteristics, the volume of the filter and the blood flow rate, the NO concentration and a distribution over time and the length of the extracorporeal circuit is established and may be used for controlling the NO level by controlling the pump of the extracorporeal circuit. The extracorporeal circuit is also compatible with pulsatile blood flows.

The device according to the present invention elutes nitric oxide (NO) from said eluting polymer in a therapeutic dose to the body fluid, such as between 0.001 to 5000 ppm, such as 0.01 to 3000 ppm, such as 0.1 to 1000 ppm, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,

75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 ppm. The
concentration may vary widely depending on where the
concentration is measured. If the concentration is measured
5 close to the actual NO eluting polymer the concentration
may be as high as thousands of ppm, while the concentration
inside the body fluid in this case often is considerably
lower, such as between 1 to 1000 ppm.

According to the present embodiment, a known
10 cardiopulmonary bypass machine is improved by adding anti-
pathogenic and/or cancerous functionality to it.

Another application of such a blood filter is during
blood donation or transfusion. While the blood bank
community has successfully implemented the higher standards
15 of viral, retroviral for reducing such pathogens in
cellular blood components, transmission of donor bacteria
is still a great infectious risk to transfusion safety. A
bacterial sepsis is regarded to be the most frequent
transfusion-associated infectious complication. By using a
20 filter device according to the above embodiment, bacteria
in donated blood are inactivated, eliminated and/or removed
shortly after collection. Alternatively, the filtering
device may be used for this purpose during blood
transfusion into the body.

25 It is known to apply leukoreduction by filtration for
the blood bank. Therefore, the NO eluting polymer is
according to another embodiment applied to such a leukocyte
filtration device in order to further reduce the likelihood
of bacterial proliferation in red cell and platelet
30 components. Such leukocyte reduction filters effectively
reduce or remove certain bacteria from blood components.

Platelet concentrates, stored at room temperature,
are most vulnerable to bacterial growth. When process
improvements cannot completely eliminate the unintended
35 entry of bacteria into blood products, the present

filtering devices may be the only way of reducing infectious risks.

Another embodiment of the invention is now described with reference to embolism filters. For instance the Pall®
5 AutoVent™ SV Blood Filter for Extracorporeal Service may be provided with NO eluting properties. This filter is designed to remove microemboli greater than 40 µm in size from perfusate during extracorporeal circulation. This includes gas emboli, fat emboli and aggregates composed of
10 platelets, red blood cells and other debris. This filter automatically separates and vents gas emboli that may be generated by pressure drops, temperature changes or oxygen oversaturation of blood. In combination with a filtering device having NO eluting polymers, or by coating the
15 existing AutoVent™ SV Blood Filter with an NO eluting polymer, embolism filters are considerably improved with the anti-pathogenic and/or anti-cancerous properties.

Gas filtering, e.g. respiratory gas filtering

20 According to the embodiment described below, the NO eluting filtering media is applied in gas filtration. Embodiments, related to respiratory gas filtering are illustrated with reference to Figs. 4 and 5.

In this way, biological pathogens like anthrax, small
25 pox and the like are treated by the NO eluting from a polymer comprised in a filter. The filter media of the present embodiment are thus able to provide such protection when e.g. incorporated into a replaceable filter cartridge of a gas mask.

30 Medical procedures in which patients share life-saving devices pose an especially high potential risk of cross infection. This may be problematic with prions due to their long incubation period where there are no signs or symptoms of disease and no tests to determine their
35 presence in humans. It is current practice in certain

anaesthesia locales to reuse the breathing circuit between patients, when a filter is used at the patient end.

Hence, a further field of application for embodiments of the invention is respiratory care.

5 Prion diseases are fatal, neurodegenerative diseases, referred to as Transmissible Spongiform Encephalopathies (TSEs), that affect both humans and animals. They include scrapie in sheep, bovine spongiform encephalopathy in cattle and variant CJD in humans. It is estimated that the
10 incubation period (prior to clinical symptoms) for variant CJD may be anywhere between 10 to 20 years. The first patient death from variant Creutzfeldt-Jacob Disease (vCJD, the human form of "mad cow disease") as a possible result of a blood transfusion has raised new concerns about the
15 potential transmission of prions during other medical procedures. One area of concern is in the use of respiratory equipment between patients during anaesthesia procedures. Studies show that up to 80 percent of aesthetic intubation procedures involve the presence of secreted
20 blood. It is known to breathing system filters in intensive care or anaesthesia endotracheal intubation procedures. The filters act as a barrier against infectious prions, and may be further improved by adding the NO eluting polymer technology to such a filter. In this way, breathing
25 circuits and ventilators are protected more effectively against patient cross contamination. Such filters are disposable single use filters, have standard connectors 41, 42 for universal fit on standard breathing circuits, and a large pleated filter surface offers minimal breathing
30 resistance. An example of such a filter 4 is shown in Fig. 4. According to an embodiment, the pleated filter surface
40 is coated with NO eluting polymers.

Such breathing circuit filters may also be used to stop the spread of SARS (severe acute respiratory
35 syndrome). In 2003 an epidemic of SARS occurred in Toronto.

The initial outbreak was characterized by nosocomial transmission. Nosocomial infections, in particular infections involving healthcare workers, have decreased, but they have not disappeared. Many of these infections appear to have occurred during procedures in intensive care units in which staff were exposed to a very high burden of respiratory secretions (high frequency oscillation, difficult intubations, bronchoscopy, non-invasive ventilation, aerosolized therapy etc.). The virus causing SARS mutated from corona virus family and is about 0.06-0.22 μ m in size. It cannot be filtered out with the expiratory isolation system which can retain bacteria of 0.3 μ m at 99.7% efficiency only. Therefore virus filters should be placed both on the inspiratory and expiratory end of the system to prevent staff contamination. Face or nose masks may also be used for patients not needing invasive ventilation. In both cases, the efficiency against SARS is improved by implementing NO eluting polymer into the filters or filtering masks.

Another topic is that the World Health Organisation (WHO) is fearing a killer flu pandemic, alarmed by the H5N1 strain of bird flu, which has become endemic in a number of Asian countries and which health officials fear could eventually mutate into a lethal new virus that will spread rapidly amongst humans.

The United Nations health agency, which sees a potential death toll of two million to seven million as a "best case scenario" for an outbreak. A more recent WHO estimate is that H5N1 could infect up to 30 percent of the world's population and kill maybe 20 to 50 million people. It will be incomparable to SARS, referring to the above-mentioned Severe Acute Respiratory Syndrome epidemic that killed 800 people around the world in 2003. While SARS had a mortality rate of around 15 percent, the deadly H5N1 strain of bird flu kills up to a third of the people it

infects. H5N1 has proven to be versatile and is able to latch itself onto more hosts. It has gone through huge genetic changes and become more pathogenic.

WHO and influenza experts worldwide are concerned
5 that the recent appearance and widespread distribution of an avian influenza -- Influenza A/H5N1 -- has the potential to ignite the next pandemic. WHO stated that it was impossible to predict just how deadly any such outbreak would be, because that would depend on various factors,
10 including the virus' virulence and the ease of transmission. However, the global spread of a pandemic cannot be stopped, but preparedness will reduce its impact. The concern is not just about the dying, it is the hundreds of millions that will be sick and who are going to flood
15 into hospitals.

With this background, the anti-pathogenic functionality added to conventional viral filters, by means of the NO eluting polymers, helps to stop such a pandemic more effectively.

20 Face masks belong to the group of personal protective equipment for breathing protection. Filtering Facepieces offer effective and economic cup shape protection. Gas masks comprising particle filters, gas filters, or combination filters are known. Respiratory protective
25 filters are a low-cost and effective means of removing contaminants from breathing air. By adding the NO eluting functionality according to the present embodiment of the invention allows them to be even more effective for pathogenic and/or cancerous elements without degrading
30 their conventional filter performance. The skilled person will appreciate that such filters are compatible with known face mask types, comprising half- and full face masks. An example for a gas mask combination filter 5 is shown in Fig. 5, wherein the filter is illustrated partly cut out.
35 One section 51 of the combination filter 5 is to filter out

gas, and the other section 52 is to filter out particles. NO eluting polymers may be added in either or both sections 51, 52.

5 Although the present invention has been described above with reference to specific embodiments, it is not intended to be limited to the specific form set forth herein. Rather, the invention is limited only by the accompanying claims and, other embodiments than the
10 specific above are equally possible within the scope of these appended claims, e.g. different arrangements of fibres, or different polymers NO eluting polymers, or different filter forms, than those described above.

 In the claims, the term "comprises/comprising" does
15 not exclude the presence of other elements or steps. Furthermore, although individually listed, a plurality of means, elements or method steps may be implemented by e.g. a single unit. Additionally, although individual features may be included in different claims, these may possibly
20 advantageously be combined, and the inclusion in different claims does not imply that a combination of features is not feasible and/or advantageous. In addition, singular references do not exclude a plurality. The terms "a", "an", "first", "second" etc do not preclude a plurality.
25 Reference signs in the claims are provided merely as a clarifying example and shall not be construed as limiting the scope of the claims in any way.

CLAIMS

1. A filtering device adapted to eliminate,
inactivate and/or remove pathogenic and/or cancerous
5 elements from fluids, especially body fluids or fluids
getting into contact with the body, comprising
a nitric oxide (NO) eluting polymer arranged to
contact said fluid when in use of said filtering device
passing there through, such that a therapeutic dose of
10 nitric oxide is eluted from said nitric oxide eluting
polymer to said fluid, characterised in that
said nitric oxide (NO) eluting polymer is a fibrous
nitric oxide (NO) eluting polymer, and
said nitric oxide is controllably elutable from said
15 fibrous nitric oxide (NO) eluting polymer upon contact with
said body fluid.
2. The filtering device according to claim 1, wherein
said pathogenic elements comprise microorganisms comprised
20 in the group of bacteria, parasites, fungi, mycoplasma,
protozoa, and viruses, and wherein said cancerous elements
are tumour cells.
3. The filtering device according to claim 1 or 2,
25 wherein said fluid is a is blood and said filtering device
is comprised in an extracorporeal circuit configured to
transport blood from a patient and/or after treatment of
blood returns treated blood to the patient.
- 30 4. The filtering device according to claim 3, wherein
said extracorporeal circuit is comprised in an
extracorporeal blood treatment apparatus, particularly
comprised in the group comprising a dialysis apparatus, an
oxygenator, or arbitrary combinations thereof.

5. The filtering device according to claim 3, wherein said filtering device is an embolism filter.

6. The filtering device according to claim 3, wherein
5 said filtering device is configured to treat a blood-borne tumour.

7. The filtering device according to claim 6, wherein
10 said blood borne tumour is leukaemia.

8. The filtering device according to claim 1 or 2,
wherein said body fluid is inspiratory or expiratory gas
entering or leaving a mammal body through the mouth or nose
15 thereof.

9. The filtering device according to claim 1, 3 or 8,
wherein fibrous nitric oxide (NO) eluting polymer is
configured to trigger release NO from said fibrous nitric
20 oxide (NO) eluting polymer by contact with humidity from
said body fluid.

10. The filtering device according to any preceding
claim, wherein said polymer is linear poly(ethylenimine)
25 (L-PEI).

11. The filtering device according to claim 1, 3 or
8, wherein said fibrous nitric oxide (NO) eluting polymer
comprises nanofibers arranged as or on a filter medium of
30 said filtering device.

12. The filtering device according to claim 11,
wherein of said nanofibers comprise poly(ethylenimine)-
diazoniumdiolate.
35

13. A process for forming a filtering device adapted to eliminate, inactivate and/or remove pathogenic elements, especially microorganisms, such as bacteria, parasites, protozoa and viruses, or cancerous elements from fluids,
5 comprising

selecting a plurality of nitric oxide eluting polymeric fibers, and

deploying said nitric oxide eluting fibers to be comprised in a filter membrane.

10

14. The process according to claim 13, wherein said deploying of fibres comprises electrospinning of nanofibers of poly(ethylenimine)-diazoniumdiolate, comprising depositing of said nanofibers on said filtering device.

15

15. A method for eliminating, inactivating and/or removing pathogenic elements, especially microorganisms, such as bacteria, parasites, fungi, mycoplasma, protozoa and viruses, or cancerous elements from fluids, comprising

20 providing a filtering device comprising a fibrous nitric oxide eluting polymer, and

eluting nitric oxide from the polymer upon contact with the fluid for achieving an anti-pathogenic and/or anti-cancerous effect.

25

16. Use of nitric oxide (NO) for adding anti-pathogenic and/or anti-cancerous functionality to an extra corporeal medical filtering device.

30

17. Use of nitric oxide (NO) eluting polymers for elution of NO from a medical filtering device for adding anti-pathogenic and/or anti-cancerous functionality to the medical filtering device.

18. Use of a nitric oxide eluting filtering device for the treatment of blood borne tumour.

19. Use according to claim 16, wherein said blood
5 borne tumour is leukaemia.

20. Use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the treatment of a blood-borne tumour.

10

21. A use as in claim 20, wherein said blood borne tumour is leukaemia.

22. NO for the treatment of a blood borne tumour.

15

23. NO for the treatment of leukaemia.

24. NO for the treatment of bird flu.

25. Use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the treatment of bird flu.

20

26. NO for the treatment of Transmissible Spongiform
25 Encephalopathies.

27. Use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the treatment of Transmissible Spongiform Encephalopathies.

30

28. NO for the treatment of Creutzfeldt-Jacob Disease.

29. Use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the treatment of Creutzfeldt-Jacob Disease.

5 30. NO for the treatment of severe acute respiratory syndrome.

31. Use of an NO eluting polymer for the manufacture of a medicament incorporated in a filtering device for the
10 treatment of severe acute respiratory syndrome.

32. The device according to any of claims 1-12, wherein said dose is inclusive between 0.001 to 5000 ppm.

15 33. The device according to claim 32, wherein said dose is inclusive between 0.01 to 3000 ppm.

34. The device according to claim 33, wherein said dose is inclusive between 0.1 to 1000 ppm.

20

35. The device according to claim 34, wherein said dose is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
25 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 ppm.

1 / 3




Fig. 1

2 / 3




Fig. 2




Fig. 3

3 / 3




Fig. 4




Fig. 5